Brain and Central Nervous System Tumors Clinical Trial
Official title:
Translation Study for Children and Adolescents With Low Grade Glioma
RATIONALE: Studying samples of tumor tissue and blood in the laboratory may help doctors
learn more about changes that occur in DNA and identify biomarkers related to cancer. It may
also help doctors understand why low-grade gliomas develop in young patients and predict how
they will respond to treatment.
PURPOSE: This clinical trial is studying tumor tissue, blood samples, and family history in
predicting tumor development and response to treatment in young patients with low-grade
glioma.
OBJECTIVES:
- To develop a better understanding of why low-grade glioma tumors develop in children
and adolescents.
- To study genetic profiles that may predict response to treatment and provide clues to
how these tumors developed initially using tumor and blood samples from these patients.
OUTLINE: This is a multicenter study.
- Retrospective data collection (for participants recruited from study SIOP-LGG1): During
a follow-up appointment for study SIOP-LGG1, both biological parents* are asked to
complete a questionnaire about their family's cancer history. They may complete the
questionnaire either in the clinic or in their home. Participants may complete and
return the questionnaires at any time throughout the study.
- Prospective data collection (for participants recruited from study SIOP-LGG-2004): Both
biological parents* are asked to complete a family history questionnaire and provide
information about their family's cancer history. Participants may complete and return
the questionnaires at any time throughout the study.
NOTE: *In circumstances where either or both biological parents are unable to complete the
questionnaire, it may be completed by the patient diagnosed with low grade glioma (if they
are over 16 years old) or adoptive parents or guardians, if they feel they have the
knowledge to complete the questionnaire.
Tumor tissue and blood samples collected on SIOP-LGG1 or SIOP-LGG-2004 are analyzed for
genetic profiles predictive of response to treatment and for different patterns of tumor
development, natural tumor behavior, and tumor sensitivity to cancer therapies. Collected
family data are anonymised and linked to the biological sample collected. Samples are then
stored for future molecular genetic studies.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00006080 -
Fenretinide in Treating Patients With Recurrent Malignant Glioma
|
Phase 2 | |
| Recruiting |
NCT00887146 -
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
|
Phase 3 | |
| Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
| Completed |
NCT00621686 -
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Terminated |
NCT00227032 -
Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme
|
Phase 1 | |
| Completed |
NCT00112502 -
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
Phase 2 | |
| Terminated |
NCT00243022 -
Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme
|
Phase 2 | |
| Active, not recruiting |
NCT00087815 -
Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain
|
N/A | |
| Active, not recruiting |
NCT00278278 -
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
Phase 3 | |
| Completed |
NCT00416819 -
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
N/A | |
| Completed |
NCT00052286 -
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
|
N/A | |
| Completed |
NCT00006093 -
EMD 121974 in Treating Patients With Progressive or Recurrent Glioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00004129 -
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
|
Phase 1 | |
| Completed |
NCT00004212 -
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Completed |
NCT00003417 -
Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
| Completed |
NCT00008008 -
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
|
Phase 2 | |
| Completed |
NCT00003484 -
Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
|
Phase 1 | |
| Completed |
NCT00003020 -
LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases
|
Phase 1 | |
| Completed |
NCT00003464 -
Temozolomide in Treating Adults With Newly Diagnosed Primary Malignant Glioblastoma Multiforme
|
Phase 2 |